Skip to Content

Posts tagged with "Drug Prices"

  • Business and Markets

    Someone Is Not Telling the Truth About Valeant

    Time to catch up briefly on one of everybody’s favorite drug companies, Valeant. Back in October, there was a lot of arguing going on about the company’s business model, and their apparent use of, well. . .creative techniques to make sure that as many prescriptions as possible were filled for their portfolio of very pricy… Read More
  • Business and Markets

    Compassion, Drug Prices, and Money

    A number of people have sent along this article from The Guardian. It’s about Jamie Love, a campaigner for cheaper pharmaceuticals. It’s a long, well-written piece, and I’ll summarize it only by saying that Love is very much opposed to the patent system, is very much a fan of compulsory licensing, and is clearly very… Read More
  • Drug Prices

    The AG of Massachusetts Has No Chance Against Gilead

    Drug prices too high? Why not just have the state Attorney General’s office set them for you? That’s what I’m taking away from this story. Maura Healy, AG of Massachusetts, is firing a warning shot at Gilead over the pricing of their HepC drugs. Her office is apparently considering whether Gilead is engaging in an… Read More
  • Drug Prices

    How Much Action Should the FDA Take?

    Biocentury has a look at the issue of compounding pharmacies, which is an area that’s been getting a lot of attention in this era of steep rises in generic drug prices. (You may recall that the competition for T*ring’s Daraprim is coming from a company that’s making the active ingredient available to compounders). The recent… Read More
  • Drug Prices

    This is the FDA’s Problem

    Here’s an article at JAMA that addresses the problem of off-patent (generic) medications in the US: they’ve traditionally been the cheapest in the industrialized world, but in recent years have been rising in price. And often spectacularly, ridiculously so. The area of concern has been the off-patent drug market with limited or no compe… Read More
  • Business and Markets

    Drug Costs, Real and Fake

    Here’s an interesting look at the price of a single orphan medication: the rattlesnake antivenom CroFab, which has already been held up as an example of “everything that’s wrong with American health care”. Rattlesnake bites are not very common, so this is a very small orphan indication. The academic developers of the antiven… Read More
  • Drug Prices

    Reciprocal Approval of Drugs, According to Ted Cruz and Mike Lee

    How many useful drugs are approved in the other industrialized countries, but not in the US? The answer to that question has changed over the years, as this Council on Foreign Relations article notes. It’s from 2001, so it’s not about recent history, but its points about the 1960s and 1970s are that the US… Read More
  • Business and Markets

    Shkreli’s Chagas Maneuver

    In case you’ve been wondering what Martin Shkreli has been up to, here’s a look at his recent appearance at a meeting put on by the folks at Forbes. “Unrepentant” would be an appropriate adjective, although I can think of some others, along with some richly descriptive nouns. He has been backing out of his statements… Read More
  • Drug Prices

    A Look At Drug Pricing

    The Wall Street Journal ran a long look yesterday at drug pricing in the US, and it’s hard to argue with this summary: The upshot is Americans fund much of the global drug industry’s earnings, and its efforts to find new medicines. . .The reasons the U.S. pays more are rooted in philosophical and practical… Read More
  • Drug Development

    The Economist’s Take On Drug Discovery

    The Economist has one of those articles that makes a person wonder. It’s a long-remarked phenomenon that whenever a newspaper writes about something that you really know, the omissions and inaccuracies that show up should make you uneasy about their coverage of everything else. And so it is here, unfortunately. The hook for the piece… Read More